Immune Cell Therapies: Advances in Cancer and Autoimmune Disease
Mar 16–19, 2025 | Fairmont Banff Springs, Banff, AB, Canada
Scientific Organizers:
Katy Rezvani, Nathan Singh and Stephan Mielke
In Person
On Demand
Mar 16–19, 2025 | Fairmont Banff Springs, Banff, AB, Canada
Scientific Organizers:
Katy Rezvani, Nathan Singh and Stephan Mielke
Available Formats:
Supported by:
In Person
On Demand
***Meeting program subject to change.
Available Formats: = In Person = On DemandMerchandise Options
Registration Options
Sunday, March 16, 2025
Fundraising
Booking Function
Registration
4:00–8:00 PM
Van Horne Foyer
Welcome Mixer
6:00–8:00 PM
Van Horne Foyer
Monday, March 17, 2025
Breakfast
7:00–8:00 AM
President's Hall
Welcome and Keynote Session (Joint)
8:00–9:30 AM
Van Horne A
* Anna Christina Obenauf, Research Institute of Molecular Pathology
Session Chair
Session Chair
* Katy Rezvani, University of Texas MD Anderson Cancer Center
Session Chair
Session Chair
Carl H. June, University of Pennsylvania
Cell Therapies: Current State-of the Art
Cell Therapies: Current State-of the Art
Ton N. Schumacher, Netherlands Cancer Institute
Dissecting T Cell Recognition of Cancer
Dissecting T Cell Recognition of Cancer
Coffee Break
9:30–9:50 AM
Van Horne Foyer
Award Recipient Acknowledgement
9:50–9:55 AM
Van Horne A
Overcoming Challenges in Immune and Cell Therapy: Insights into Mechanisms of Failure and Solutions (Joint)
9:55–12:00 PM
Van Horne A
* Nathan Singh, Washington University School of Medicine
Genomic Regulation of CAR-Driven T Cell Dysfunction
Genomic Regulation of CAR-Driven T Cell Dysfunction
* Anna Christina Obenauf, Research Institute of Molecular Pathology
Rational Combination of Therapies to Stimulate the APC Compartment
Rational Combination of Therapies to Stimulate the APC Compartment
May Daher, MD Anderson Cancer Center
Metabolic Interventions to Enhance Adoptive Cellular Therapies
Metabolic Interventions to Enhance Adoptive Cellular Therapies
Christopher Harvey, Phenomic
AI/ML-Driven Discovery of a Novel Proteoglycan for Precision Targeting of Solid Tumors by T Cell Engagers
AI/ML-Driven Discovery of a Novel Proteoglycan for Precision Targeting of Solid Tumors by T Cell Engagers
Poster Setup
12:00–1:00 PM
Van Horne C
On Own for Lunch
12:00–2:30 PM
Poster Viewing
1:00–10:00 PM
Van Horne C
Symposia Spotlight 1: Late-breaking research presentations selected from abstract submissions
2:30–4:30 PM
Van Horne A
* Stephan Mielke, Karolinska Institutet
Session Chair
Session Chair
Xinchen Wang, Waypoint Bio
In Vivo Spatial Pooled Screening Identifies CAR T Constructs with Superior Anti-Solid Tumor Efficacy and Safety
In Vivo Spatial Pooled Screening Identifies CAR T Constructs with Superior Anti-Solid Tumor Efficacy and Safety
Ju-Fang Chang, Washington University in St Louis
Generation of MHC-Independent T Cell Receptors Using Rational Protein Engineering
Generation of MHC-Independent T Cell Receptors Using Rational Protein Engineering
Reno Debets, Erasmus MC Cancer Institute
Human T Cell Receptors Equipped with Inducible Co-Stimulator Mediate Durable Anti-Tumor Activity
Human T Cell Receptors Equipped with Inducible Co-Stimulator Mediate Durable Anti-Tumor Activity
Hector Caballero Gonzalez, Cellply Srl
Single-Cell Profiling Reveals Functional Dynamics Of Adapter CAR-T Cells Targeting CD33+ Acute Myeloid Leukemia
Single-Cell Profiling Reveals Functional Dynamics Of Adapter CAR-T Cells Targeting CD33+ Acute Myeloid Leukemia
Jemma Larson, University of Minnesota
Striking a Balance: Human CAR19+ CD8-Itreg for Prevention of GVHD And Enhanced Anti-Leukemic Efficacy Without Systemic Toxicity
Striking a Balance: Human CAR19+ CD8-Itreg for Prevention of GVHD And Enhanced Anti-Leukemic Efficacy Without Systemic Toxicity
Yinghui Jane Huang, University of Pennsylvania
Continuous Expression of TOX Safeguards Exhausted CD8 T Cell Epigenetic Fate
Continuous Expression of TOX Safeguards Exhausted CD8 T Cell Epigenetic Fate
Corbett Berry, University of Pennsylvania
Asymmetric Epigenetic and Metabolic Remodeling of Engineered CD4 T Cells Drives Divergent Cell Fate
Asymmetric Epigenetic and Metabolic Remodeling of Engineered CD4 T Cells Drives Divergent Cell Fate
Grant G Welstead, Century Therapeutics
Generation of iPSC-Derived CD4+ and CD8+ CD19 CAR T Cells with Robust in Vivo Tumor Control and Persistence
Generation of iPSC-Derived CD4+ and CD8+ CD19 CAR T Cells with Robust in Vivo Tumor Control and Persistence
Zoila I Fernandez, Stanford University
Myeloid Cell States as Regulators Of CAR-T Cell Function
Myeloid Cell States as Regulators Of CAR-T Cell Function
Coffee Available
4:30–5:00 PM
Van Horne Foyer
Cell Therapies for Solid Tumors
5:00–7:00 PM
Van Horne A
Nicholas Vitanza, Seattle Children’s / University of Washington
Advancing Locoregional CAR T Cell Therapy for Pediatric CNS Tumors
Advancing Locoregional CAR T Cell Therapy for Pediatric CNS Tumors
* Marcela V. Maus, Harvard Medical School
Driving Complex CAR-T into the Clinic – What, Why, and How
Driving Complex CAR-T into the Clinic – What, Why, and How
Andras Heczey, Baylor College of Medicine
Cytokine Armored GPC3-CAR T Cells for Patients with Solid Tumors
Cytokine Armored GPC3-CAR T Cells for Patients with Solid Tumors
Tori Yamamoto, Gladstone Institutes
Short Talk: In Vivo CRISPRa Screens Uncover Positive and Negative Regulators of T Cell Accumulation in the Immunocompetent Tumor Microenvironment
Short Talk: In Vivo CRISPRa Screens Uncover Positive and Negative Regulators of T Cell Accumulation in the Immunocompetent Tumor Microenvironment
Filippo Birocchi, MGH
Short Talk: Balancing Efficacy and Safety: Overcoming On-Target Off-Tumor Toxicity of Claudin18.2-Directed CAR-T Cells in Preclinical Models
Short Talk: Balancing Efficacy and Safety: Overcoming On-Target Off-Tumor Toxicity of Claudin18.2-Directed CAR-T Cells in Preclinical Models
Social Hour with Lite Bites
7:00–8:00 PM
President's Hall
Poster Session 1
7:30–10:00 PM
Van Horne C
Tuesday, March 18, 2025
Breakfast
7:00–8:00 AM
President's Hall
Diversity, Access and Pathways to Regulatory Approval
8:00–10:00 AM
Van Horne A
Stephan Mielke, Karolinska Institutet
CAR T Cells: A European Perspective
CAR T Cells: A European Perspective
* Rayne H. Rouce, Baylor College of Medicine
Improving Access to Cell Therapies
Improving Access to Cell Therapies
Coffee Break
9:00–9:20 AM
Van Horne Foyer
Poster Setup
10:00–1:00 PM
Van Horne C
On Own for Lunch
10:00–5:00 PM
Poster Viewing
1:00–10:00 PM
Van Horne C
Career Roundtable (Joint)
3:00–4:30 PM
Van Horne B
Wolfgang Karl Kastenmueller, Institute of Systems Immunology, Max-Planck Research Group
Professor and Director
Professor and Director
Rayne H. Rouce, Baylor College of Medicine
Associate Professor
Associate Professor
Kristian Hedstrom, Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Chief Scientific Officer
Chief Scientific Officer
Frank P Stegmeier, Curie.Bio
CSO Partner
CSO Partner
Fabiola V Rivas, Immunity
Deputy Editor
Deputy Editor
Coffee Available
4:30–5:00 PM
Van Horne Foyer
Cell Therapy for Autoimmune Diseases
5:00–7:00 PM
Van Horne A
* Andreas Mackensen, University Hospital of Erlangen
CAR T Cells for B-cell mediated Autoimmune Disease
CAR T Cells for B-cell mediated Autoimmune Disease
Gwendolyn Binder, Cabaletta Bio
Clinical and Translational Development of Engineered T Cell Therapy for Autoimmune Disease
Clinical and Translational Development of Engineered T Cell Therapy for Autoimmune Disease
Megan K. Levings, University of British Columbia
CAR Tregs
CAR Tregs
Eleanor Chen, The University of British Columbia
Short Talk: Alloantigen-Specific CAR Tregs Mediate Islet Protection By Suppressing Islet Autoantigen-Specific T Cells
Short Talk: Alloantigen-Specific CAR Tregs Mediate Islet Protection By Suppressing Islet Autoantigen-Specific T Cells
Social Hour with Lite Bites
7:00–8:00 PM
President's Hall
Poster Session 2
7:30–10:00 PM
Van Horne C
Wednesday, March 19, 2025
Breakfast
7:00–8:00 AM
President's Hall
Alternative Immune Effectors
8:00–11:00 AM
Van Horne A
* May Daher, MD Anderson Cancer Center
Session Chair
Session Chair
Michael Klichinsky, Carisma Therapeutics
Remote Presentation: CAR-M: Engineering Myeloid Cells ex vivo and in vivo for Cancer Immunotherapy
Remote Presentation: CAR-M: Engineering Myeloid Cells ex vivo and in vivo for Cancer Immunotherapy
Katy Rezvani, University of Texas MD Anderson Cancer Center
Engineering NK Cells for Cancer Immunotherapy
Engineering NK Cells for Cancer Immunotherapy
Jode Goodridge, Fate Therapeutics
Use of iPSC for Programmed Cellular Immunotherapies
Use of iPSC for Programmed Cellular Immunotherapies
Jurgen Kuball, University Medical Center
Mastering Diversity of gdT Cells and the Receptors for Cancer Immune Therapies
Mastering Diversity of gdT Cells and the Receptors for Cancer Immune Therapies
Shelby Namen, Washington University in St. Louis
Short Talk: CAR Engineered Dcs Respond to Tumor in a Signaling Distinct Manner
Short Talk: CAR Engineered Dcs Respond to Tumor in a Signaling Distinct Manner
Yeara Jo, University of California, Berkeley
Short Talk: Elucidating Molecular Mechanisms of NK Cell Function from the Studies of NK Cell Desensitization and Exhaustion for Improved Anti-Cancer Therapies
Short Talk: Elucidating Molecular Mechanisms of NK Cell Function from the Studies of NK Cell Desensitization and Exhaustion for Improved Anti-Cancer Therapies
Coffee Break
9:00–9:20 AM
Van Horne Foyer
On Own for Lunch
11:00–2:30 PM
Symposia Spotlight 2: Late-breaking research presentations selected from abstract submissions
2:30–4:30 PM
Van Horne A
* Mark Leick, Massachusetts General Hospital Cancer Center
Session Chair
Session Chair
Maxwell Foisey, University of California San Francisco
Hybrid-R: Overcoming Limitations in T Cell Therapy With A Single Synthetic Receptor
Hybrid-R: Overcoming Limitations in T Cell Therapy With A Single Synthetic Receptor
Robert J. Hofmeister, Myeloid Therapeutics
Innate Immune Receptor-Based Cars For In Vivo Programming of Myeloid Cells to Combat Solid Tumors
Innate Immune Receptor-Based Cars For In Vivo Programming of Myeloid Cells to Combat Solid Tumors
Alexander Kim, Washington University School of Medicine
Amyloid Plaque Targeting Chimeric Antigen Receptor Macrophages for Alzheimer’s Disease Therapy
Amyloid Plaque Targeting Chimeric Antigen Receptor Macrophages for Alzheimer’s Disease Therapy
Clara Soulard, CHU Sainte Justine
Exploring the Potential Of CAR-Engineered Hscs for Treating B-Cell Acute Lymphoblastic Leukemia
Exploring the Potential Of CAR-Engineered Hscs for Treating B-Cell Acute Lymphoblastic Leukemia
Kevin Salim, BC Children's Hospital Research Institute/University of British Columbia
Differentiation of Human CD4+ T Cells from Pluripotent Stem Cells
Differentiation of Human CD4+ T Cells from Pluripotent Stem Cells
Ritu Bohat, MD Anderson Cancer Center
Enhancing CAR-NK Potency and Persistence with Myd88/CD40 Costimulation
Enhancing CAR-NK Potency and Persistence with Myd88/CD40 Costimulation
Coffee Available
4:30–5:00 PM
Van Horne Foyer
Engineering in Cancer Immunotherapy to Enhance Efficacy (Joint)
5:00–6:30 PM
Van Horne A
Rosandra Natasha Kaplan, NCI, National Institutes of Health
Remote Presentation: Engineering of Myeloid Cells
Remote Presentation: Engineering of Myeloid Cells
Jaehyuk Choi, Northwestern University
Nature Inspired Design
Nature Inspired Design
* Julia Carnevale, University of California, San Francisco
CRISPR-Based T Cell Editing to Enhance Cell Therapy
CRISPR-Based T Cell Editing to Enhance Cell Therapy
Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (Joint)
6:30–7:00 PM
Van Horne A
Social Hour with Lite Bites
7:00–8:00 PM
President's Hall
Entertainment
8:00–9:00 PM
Van Horne B
Thursday, March 20, 2025
Departure
12:00–11:59 PM
Subscribe for Updates